Table 2 SEC13, GHRL, lncRNA GHRLOS, SMAD7, HIF-1α genes expression, serum HIF-1α (ng/ml) and CEA level (ng/ml) in control and gastric cancer patients' groups.

From: Gene profiling of SEC13, SMAD7, GHRL, long non-coding RNA GHRLOS, HIF-1α in gastric cancer patients

Control (n = 50)

Gastric cancer patients (n = 50)

P

SEC13 gene

4.50 ± 12.12

0.34 ± 0.42

 < 0.001*

0.72 (0.28–2.7)

0.18 (0.12–0.33)

GHRL gene

4.87 ± 7.48

1.32 ± 3.40

0.025*

0.51 (0.20–6.0)

0.34 (0.11–0.78)

LncRNA GHRLOS

3.28 ± 7.74

0.11 ± 0.52

 < 0.001*

0.88 (0.49–1.60)

0.17 (0.09–0.78)

SMAD7 gene

4.48 ± 8.60

5.36 ± 12.04

0.024*

0.56 (0.28–3.6)

1.56 (0.59–5.20)

HIF-1α gene

3.81 ± 6.56

5.60 ± 6.40

 < 0.001*

0.65 (0.24–5.39)

4.81 (1.37–7.21)

HIF-1α protein

17.64 ± 4.12

191.6 ± 43.94

 < 0.001*

19.10 (16.60–20.40)

198.7 (167.0–224.2)

CEA protein

2.93 ± 1.01

71.77 ± 45.91

 < 0.001*

3.02 (2.20–3.60)

84.50 (37.0–97.0)

  1. Mean ± S.D. and Median (IQR).
  2. n: number of cases.
  3. P: P value for comparing between GC patients and control group utilizing Mann Whitney test.
  4. *Significance at P ≤ 0.05.
Back to article page